Company news
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) news
Arcturus Therapeutics Holdings Inc. news releases on 6ix. Latest, Sep 23, 2026: Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results…
Press releases & updates
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
September 23, 2026
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
September 18, 2026
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
August 31, 2026
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
August 6, 2026
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
July 27, 2026
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
July 1, 2026
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 26, 2026
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
May 7, 2026
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
April 27, 2026
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
March 3, 2026
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
February 17, 2026
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conference
November 23, 2025
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
November 9, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
November 3, 2025
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
October 27, 2025
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
October 21, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
August 10, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 23, 2025
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 29, 2025
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
June 22, 2025
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 11, 2025
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
April 21, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
April 9, 2025
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
March 5, 2025
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
March 4, 2025
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
February 23, 2025
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 13, 2025
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 13, 2025
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
February 3, 2025
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
January 30, 2025
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
January 9, 2025
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 5, 2025
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 15, 2024
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
November 17, 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
November 10, 2024
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
November 6, 2024
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
October 30, 2024
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 29, 2024
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 12, 2024
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 12, 2024
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 2, 2024
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 26, 2024
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 4, 2024
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
July 31, 2024
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 17, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
June 30, 2024
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 19, 2024